# Retatrutide NEJM 2023 Phase 2 Obesity Results

URL: https://moleculenotes.com/clinical-trials-and-research/retatrutide-nejm-2023-phase-2-obesity
Published: 2026-04-18
Updated: 2026-04-18
Author: Admin
Category: Clinical Trials & Research
Reading time: 13 min

> Explore the retatrutide NEJM 2023 phase 2 obesity trial results showing 24.2% weight loss. Read more to understand its potential in obesity treatment.

---

When the [New England Journal of Medicine published the Phase 2 data](https://www.nejm.org/doi/full/10.1056/NEJMoa2204470) for retatrutide (LY3437943) in 2023, it drew immediate attention across metabolic medicine and peptide research communities, and for good reason. Participants on the highest dose arm lost a mean of 24.2% of their body weight over 48 weeks, a figure that surpassed every previously reported outcome in a [randomized controlled trial of any anti-obesity pharmacotherapy](https://www.clinicaltrials.gov/ct2/show/NCT04881760). But a single headline number, however striking, does not fully capture what the trial design, dose-response architecture, cardiometabolic endpoints, and safety profile collectively reveal about this molecule's potential. This article provides a structured, mechanistically grounded breakdown of the retatrutide NEJM 2023 phase 2 obesity trial — what was measured, how the study was designed, what the data actually showed across all arms, and what the 48-week non-plateau trajectory signals for Phase 3.

## What Makes Retatrutide Mechanistically Different: The Triple Agonist Architecture

Retatrutide engages three distinct G protein-coupled receptors, each with a separate metabolic role. GLP-1R activation drives appetite suppression and glucose-dependent insulin secretion. GIPR activation potentiates insulin release and, critically, appears to attenuate the gastrointestinal side effects that typically limit dose escalation in pure GLP-1R agonists. GCGR activation increases basal energy expenditure and promotes hepatic fat oxidation, a mechanism entirely absent from incretin-only agents. [Advances in peptide agonist design](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952442/) highlight how multi-receptor targeting can optimize metabolic outcomes.

The pharmacological lineage leading to retatrutide follows a clear progression. First-generation GLP-1R monoagonists, including exenatide, liraglutide, and semaglutide, established incretin-based therapy as a viable obesity treatment strategy. Tirzepatide then introduced GIPR co-agonism alongside GLP-1R engagement, producing meaningfully greater weight loss than monoagonists. Retatrutide adds the glucagon receptor layer, completing the triple agonist architecture and extending metabolic coverage beyond what either prior generation could achieve. The weight loss outcomes across these generations reflect this step-wise progression: semaglutide achieved roughly 15% at 68 weeks, tirzepatide approximately 22.5% at 72 weeks, and retatrutide 24.2% at just 48 weeks.

Structurally, retatrutide is an acylated peptide derived from a modified glucagon analog backbone. A C18 fatty diacid moiety is attached via a linker to a lysine residue in the peptide chain, enabling reversible binding to circulating serum albumin. This binding reduces both renal clearance and proteolytic degradation, extending plasma half-life to approximately one week and providing the pharmacokinetic basis for once-weekly subcutaneous dosing. The strategy mirrors the acylation approach used in semaglutide, though retatrutide's backbone is engineered for high-affinity activity at all three receptors simultaneously.

The glucagon receptor component is the most pharmacologically novel element. GCGR agonism was historically viewed with skepticism in obesity treatment because glucagon promotes hepatic glucose output, raising concerns about glycemic safety. In the context of combined GLP-1R and GIPR engagement, however, the insulin-secreting effects of the incretin receptors appear to offset the hyperglycemic risk of GCGR activation, while the energy expenditure and lipolytic benefits of glucagon signaling are preserved. This mechanistic synergy is what fundamentally differentiates retatrutide from tirzepatide.

## Phase 2 Trial Design: Enrollment, Dose Arms, and What Was Being Measured

![Clinical trial setting illustrating phase 2 trial design for retatrutide NEJM 2023 phase 2 obesity study](https://pub-0704c478f1494034b5187465be51bbc3.r2.dev/sites/cmnq5qrg50001e4xw09xcflvu/2026/04/0ca29156-afba-44b0-b922-65b3ea04a8c7-full.webp)

Clinical trial setting illustrating phase 2 trial design for retatrutide NEJM 2023 phase 2 obesity study

The obesity-focused Phase 2 trial, registered as [NCT04881760](https://clinicaltrials.gov/ct2/show/NCT04881760), enrolled 338 adults with either obesity or overweight accompanied by at least one weight-related comorbidity. Participants were randomized across four active dose arms and a placebo group, receiving retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg once weekly over 48 weeks. The design was intentionally dose-ranging, constructed to characterize the dose-response relationship rather than confirm a single therapeutic dose.

Each active arm used a structured dose escalation protocol. Participants did not begin at their assigned maintenance dose; instead, they titrated upward over several weeks, a design choice that directly reflects real-world tolerability management for GLP-1R agonist class drugs. Rapid dose escalation in this drug class reliably increases gastrointestinal adverse event rates, so the stepped protocol was both scientifically and clinically informed.

The primary endpoint was percent change in body weight from baseline at 48 weeks. Secondary endpoints spanned a broad range of cardiometabolic and glycemic markers. These included HbA1c, fasting glucose, insulin resistance assessed by HOMA-IR, systolic blood pressure, fasting triglycerides, and waist circumference. The breadth of secondary endpoints reflects the trial's intent to characterize retatrutide's metabolic profile beyond simple weight reduction, providing early evidence across the full spectrum of obesity-related pathophysiology.

It is worth clarifying the scope of the evidence being discussed here. A separate Phase 2 trial, [NCT05019755](https://clinicaltrials.gov/ct2/show/NCT05019755), was conducted specifically in patients with type 2 diabetes, with glycemic control as the primary focus. The data reviewed in this article comes from the obesity-focused [NEJM publication](https://jamanetwork.com/journals/jama/fullarticle/2807066). Both trials contribute to the overall retatrutide evidence base, but they address distinct clinical populations and should not be conflated when interpreting results.

## Primary Endpoint: The 24.2% Weight Loss Finding in Context

![Visual representation of 24.2% weight loss primary endpoint in retatrutide NEJM 2023 phase 2 obesity trial](https://pub-0704c478f1494034b5187465be51bbc3.r2.dev/sites/cmnq5qrg50001e4xw09xcflvu/2026/04/30e921b7-8a7b-4cd8-9e36-d4d7a329f024-full.webp)

Visual representation of 24.2% weight loss primary endpoint in retatrutide NEJM 2023 phase 2 obesity trial

The dose-dependent weight loss results across all arms were unambiguous. At 48 weeks, the 1 mg arm produced a mean body weight reduction of approximately 8.7%, the 4 mg arm approximately 17.3%, the 8 mg arm approximately 22.8%, and the 12 mg arm 24.2%, compared to a 2.1% reduction in the placebo group. The dose-response relationship was clean and monotonic across the full dose range, a pattern that strengthens confidence in the drug's pharmacological signal rather than attributing outcomes to statistical noise.

The 24.2% figure becomes more striking when placed alongside the best available comparators. In the STEP 1 trial, semaglutide 2.4 mg produced approximately 15% mean weight loss at 68 weeks. In SURMOUNT-1, tirzepatide 15 mg achieved approximately 22.5% at 72 weeks. Retatrutide's 12 mg arm exceeded both, and did so over a shorter treatment duration of 48 weeks. The breakdown illustrates a consistent escalation in efficacy across pharmacological generations, with retatrutide representing the current ceiling of observed weight loss in controlled trials.

The most consequential observation in the primary endpoint data may not be the 24.2% figure itself, but what the weight loss trajectories looked like at week 48. In higher-dose arms, the curves had not plateaued. Weight loss was still progressing at the final assessment timepoint. This non-plateau signal is a critical differentiator from earlier agents, where weight loss curves typically leveled off by 52 to 68 weeks. If the trajectory in the 8 mg and 12 mg arms continues in Phase 3 trials conducted over 72 to 104 weeks, the true efficacy ceiling of this molecule may exceed what Phase 2 could capture.

Preclinical data had provided early mechanistic rationale for this level of efficacy. Animal models comparing triple GLP-1R/GIPR/GCGR agonism to dual agonism showed greater reductions in body fat mass and more pronounced improvements in hepatic steatosis. The Phase 2 human data appears to validate that preclinical signal at clinically meaningful scale.

## Secondary Endpoints: Cardiometabolic and Glycemic Improvements Beyond the Scale

The glycemic data from the Phase 2 trial was particularly notable for participants with elevated baseline glucose. In this subgroup, retatrutide reduced HbA1c by up to 2.02 percentage points, a reduction comparable to dedicated glucose-lowering therapies. Fasting glucose and HOMA-IR also improved significantly versus placebo, consistent with the dual insulin-secreting mechanism of GLP-1R and GIPR co-activation alongside reductions in hepatic glucose output.

Cardiometabolic secondary endpoints showed statistically significant improvements across multiple markers. Systolic blood pressure decreased meaningfully versus placebo. Fasting triglycerides fell substantially, with the highest dose arm showing the most pronounced reductions. Waist circumference, a clinically relevant proxy for visceral adiposity, also decreased significantly. These numbers highlight a cardiometabolic profile that extends well beyond weight reduction alone, suggesting retatrutide may address multiple components of metabolic syndrome simultaneously.

The waist circumference and triglyceride data carry particular mechanistic significance. Visceral adipose tissue is metabolically active in ways that subcutaneous fat is not, and its reduction is more directly linked to cardiovascular and hepatic risk than total weight loss. The GCGR agonism component likely contributes here through enhanced hepatic fatty acid oxidation, reducing both ectopic fat deposition and circulating lipid burden in ways that incretin-only agents cannot fully replicate.

Early signals relevant to NASH, now termed MASH, are also worth noting. Retatrutide's mechanism presents a triad of hepatically relevant effects. [GLP-1 receptor activation](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313445/) reduces hepatic lipogenesis. [GLP-1R and GIPR engagement](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448664/) together improve insulin sensitivity, reducing the hyperinsulinemia that drives de novo lipogenesis. GCGR activation increases hepatic fatty acid oxidation, further reducing hepatic lipid accumulation. Whether this mechanistic triad translates to histological improvement in MASH is a question Phase 3 must answer directly, but the secondary endpoint lipid data provides an encouraging early signal.

## Safety and Tolerability Profile: What the Adverse Event Data Shows

The adverse event profile of retatrutide in the Phase 2 trial was consistent with the established GLP-1R agonist drug class. Nausea, vomiting, diarrhea, and constipation were the most commonly reported events across active dose arms. The majority of these events were mild to moderate in severity and were most frequent during dose escalation phases, consistent with the known mechanism of GLP-1R activation in the gastrointestinal tract.

Discontinuation rates were dose-dependent but remained within a range seen with other agents in this class. The 1 mg arm showed discontinuation rates comparable to placebo, while the 12 mg arm had higher rates, though the structured dose escalation protocol appeared to mitigate peak GI burden. The potential contribution of GIPR co-agonism to improved tolerability is worth noting. Evidence suggests that GIP receptor activation in the central nervous system may attenuate the nausea associated with GLP-1R stimulation, and the relatively favorable tolerability of tirzepatide versus pure GLP-1R agonists at equivalent weight loss outcomes has been attributed in part to this mechanism. [GIP co-agonism and tolerability](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526204/) remain areas of active investigation.

No serious novel safety signals emerged in the Phase 2 data. This is a meaningful observation, but it should be contextualized appropriately. A 48-week Phase 2 trial with 338 participants is not powered to detect rare adverse events, and the duration is insufficient to characterize long-term safety signals. Regulatory approval for obesity pharmacotherapy now routinely requires cardiovascular outcomes data from large, multi-year trials, and Phase 2 data simply cannot substitute for that evidence base.

One area deserving attention as Phase 3 data emerges is bone and musculoskeletal health. GIPR agonism has known anabolic effects in bone tissue, which may differentiate retatrutide's skeletal profile from pure GLP-1R agents. Given that significant weight loss by any mechanism can reduce bone mineral density and lean mass, whether retatrutide's GIPR component partially preserves these outcomes is a clinically meaningful question that Phase 2 was not designed to answer definitively.

## What the 48-Week Non-Plateau Tells Us — and What Phase 3 Must Answer

The non-plateau weight loss trajectory observed at week 48 in the highest dose arms of the retatrutide NEJM 2023 phase 2 obesity trial is, in isolation, one of the most important signals in the dataset. When weight loss curves have not leveled off at 48 weeks, it implies that the biological equilibrium between drug effect and physiological counter-regulation has not yet been reached. Phase 3 trials designed for 72 to 104 weeks may therefore reveal meaningfully greater absolute efficacy, and raise the question of what the true weight loss ceiling for this molecule actually is.

Eli Lilly has initiated the Phase 3 [TRIUMPH program](https://clinicaltrials.gov/ct2/show/NCT05597715) in obesity and a parallel arm in type 2 diabetes, with results anticipated in 2025 and 2026. These trials will need to address the clinical questions that Phase 2, by design, cannot answer. Long-term cardiovascular outcomes data is a regulatory prerequisite for broad obesity drug approval, as established by the FDA's post-market requirements for agents in this class. Whether retatrutide reduces major adverse cardiovascular events in a powered outcomes trial is currently unknown.

Phase 3 must also address several additional gaps. No powered head-to-head comparison between retatrutide and tirzepatide or semaglutide currently exists, making it impossible to quantify the incremental efficacy of the glucagon receptor component in a controlled comparative setting. Durability of weight loss after treatment discontinuation is also uncharacterized; this matters enormously for clinical decision-making, particularly given the evidence that weight regain after GLP-1R agonist cessation is substantial. The Phase 2 population also lacked sufficient ethnic diversity to characterize differential responses across populations, a gap with regulatory and public health implications.

The commercial context surrounding these data is substantial. Goldman Sachs has projected the global obesity drug market will exceed $100 billion annually by 2030. Retatrutide's Phase 2 profile positions it as a potential market leader if Phase 3 results confirm and extend what Phase 2 showed. The competitive and scientific stakes of the TRIUMPH readouts are therefore difficult to overstate, both for Eli Lilly and for the broader trajectory of obesity pharmacotherapy as a field.

### Peptide Chemistry Perspective: Engineering Potency, Selectivity, and Half-Life in One Molecule

Retatrutide's amino acid backbone is derived from a modified glucagon analog, engineered at specific residue positions to achieve simultaneous high-affinity binding at GLP-1R and GIPR while maintaining therapeutically meaningful but controlled activity at GCGR. Balancing agonist potency across three structurally distinct GPCRs, each with different endogenous ligands and binding pocket geometries, requires iterative structural optimization at the peptide level. Achieving this balance without introducing receptor bias or off-target activation represents a significant medicinal chemistry accomplishment. [Peptide engineering in multi-receptor targeting](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171757/)

The fatty acid acylation strategy central to retatrutide's design follows the same pharmacokinetic logic as semaglutide. A C18 fatty diacid chain attached via a linker to a lysine residue in the peptide backbone enables reversible, non-covalent binding to serum albumin, a 66 kDa plasma protein. This albumin association reduces renal filtration and slows proteolytic degradation, extending plasma half-life to approximately one week. The specific chain length and linker chemistry are not incidental; both critically determine the affinity and reversibility of albumin binding, and thus the duration of pharmacological action.

The broader significance of retatrutide's design lies in what it demonstrates about the current frontier of therapeutic peptide engineering. A single acylated peptide scaffold has been made to engage three structurally distinct GPCRs with therapeutically calibrated potency at each, while simultaneously achieving the pharmacokinetic profile required for once-weekly clinical dosing. This multi-receptor G protein-coupled receptor agonism via a single peptide scaffold approach is likely to inform the design of next-generation metabolic peptides beyond retatrutide, whether targeting additional receptor combinations or applying the same acylation and backbone engineering strategies to other disease areas.

The retatrutide NEJM 2023 phase 2 obesity dataset represents, by the metrics currently available, the most compelling pharmacological weight loss evidence published in a controlled trial setting. The 24.2% mean weight loss at 48 weeks, the clean dose-response architecture, the non-plateau trajectory in higher dose arms, and the breadth of cardiometabolic improvements across secondary endpoints collectively indicate a molecule operating at a genuinely different level of efficacy than its predecessors. The glucagon receptor component, once considered a pharmacological liability, appears to be a meaningful contributor to outcomes through energy expenditure and hepatic fat oxidation mechanisms that dual agonists cannot replicate.

That said, Phase 2 data carries inherent limitations. The sample was modest in size, the duration was insufficient for cardiovascular outcomes characterization, and no head-to-head trials against approved agents exist. The Phase 3 TRIUMPH program, with data expected in 2025 to 2026, will determine whether these Phase 2 signals hold at scale, over longer follow-up, and across more diverse populations. For researchers and clinicians tracking the evolution of metabolic pharmacotherapy, retatrutide represents both a scientific milestone and an unfinished story, one whose next chapter will carry significant clinical and commercial consequences.